Skip to main content

Juul Fails To Block Vaping Products Trial

Juul Fails To Block Vaping Products Trial

Juul Fails To Block Vaping Products Trial

Introduction

JuuL Labs Inc. has failed to block the first trial from 2,500 personal injury cases against the e-cigarette maker, which accuses the company of marketing vaping products targeting minors.

As per the court documents, a Tennessee woman alleged that her daughter developed an addiction to using the company's vaping products at the age of 12. The company requested the court to dismiss the claims in the lawsuit, but U.S. District Judge William Orrick rejected the company's plea.

The company stated in its defense that the claims are meritless as the teen failed to identify any specific advertisement which encouraged her to use the JuuL products. The court filings of the company even notified that bright colors and young models, which were used to promote the products were just an exaggerated marketing strategy  which should not be taken seriously.

In 2020, the legal problems for Juul increased after a 39-state probe was announced into its teen marketing. The company's popularity increased, resulting in domination of the e-cigarette market. The success eventually brought the company into limelight which was noticed by the federal regulators and state attorneys general who were concerned about the impact of the products on teenagers.

JuuL will face six bellwether trials which allege that the company used illegal marketing strategies and targeted minors to boost their sale resulting in nicotine addiction among the youths. The first bellwether trial is scheduled to start on June 16.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!